Overleving longkanker
De vijfjaarsoverleving van longkanker is de afgelopen dertig jaar verbeterd van 12% in 1991-2000 naar 21% in 2011-2018.
Algemene trend
NSCLC I-III
Stadium I
De vijfjaarsoverleving is bij stadium I duidelijk beter dan bij hogere stadia. Na chirurgische behandeling is de vijfjaarsoverleving 71% versus 41% na radiotherapie. Dit verschil in overleving wordt deels verklaard door verschillen in patiëntkarakteristieken.
Relevante publicaties:
- Centralization of lung cancer surgery in the Netherlands: differences in care and survival of patients with stage I non-small cell lung cancer between hospitals with and without in-house lung cancer surgery.
- The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands.
- Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I nonsmall cell lung cancer in elderly patients: a propensity matched comparative ana